The inventions described below relate to the field of CPR.
The AutoPulse® chest compression device is used to provide chest compressions during the course of CPR in reviving a cardiac arrest victim. The AutoPulse® provides compressions according to a predetermined compression waveform which is optimized for a large variety of potential victims. We have previously proposed feedback control, based on sensed biological parameters, to alter the compression waveform applied by the chest compression device. The biological parameters proposed, including end-tidal CO2 and blood oxygen levels, are readily measured with non-invasive devices.
The operation of chest compression devices can be improved with the use of more fundamental biological parameters, such as aortic blood flow volume, the aortic pulse pressure waveform, and other blood vessel parameters, as feedback for control of the chest compression device. Depending on the value of aortic blood flow volume and blood vessel parameters, the compression waveform provided by the chest compression device may be varied. The compression waveform may be varied from patient to patient, depending on the value of aortic blood flow volume and/or blood vessel parameters measured before or at the commencement of chest compressions. The compression waveform may be varied during the course of CPR chest compression on a single patient, depending on the value of aortic blood flow volume and/or blood vessel parameters measured over the course of resuscitation efforts and chest compressions. Chest compression waveform characteristics such as compression depth, compression rate, compression rise time, compression hold time, and release velocity can be varied to optimize compression induced blood flow in the cardiac arrest victim.
Adjunct therapies, especially the administration of epinephrine, can be implemented, modified or avoided based on information gleaned from the biological parameters, such as arterial stiffness and/or pulse wave velocity.
A number of terms relating to blood flow parameters are used in the art, including the following:
The pulse pressure waveform is a depiction of pressure versus time in a particular blood vessel.
SPTI refers to the systolic pressure-time integral, which is the area under the central aortic pressure wave curve during the systole portion of a heartbeat (when the left ventricle is contracting). SPTI is also referred to as left ventricular load, or LV load. Systole is that portion of the heartbeat starting at the closure of the atrioventricular (cuspid) valves and ending with the closure of the aortic valve.
DPTI refers to the diastolic pressure-time integral, which is the area under the central aortic pressure wave curve during the diastole portion of a heartbeat (when the heart left ventricle is relaxing). Diastole is that portion of the heartbeat in which the heart is relaxing, starting with closure of the aortic valve and ending with the subsequent closure of the atrioventricular valves.
Arterial Compliance, a measure of the stiffness, refers to the mechanical characteristic of blood vessels throughout the body. If refers to the ability or inability of blood vessels to elastically expand in response to pulsatile flow. It is quantified in terms of ml/mm Hg (the change in volume due to a given change in pressure). Elastance is a reciprocal concept, and refers to the tendency of blood vessels to recoil after distension. In relation to the aorta, aortic compliance/elastance affects the ability of the aorta to expand and contract during and after contraction of the heart which forces blood from the left ventricle.
The aortic pulse pressure waveform can be determined non-invasively, based on peripheral pulse waveforms obtained with sensors mounted on the patient. Sensors can measure pressure and/or velocity at superficial locations of the radial artery, brachial artery, carotid and/or femoral artery. Various known models and “transfer functions” can be used to determine the aortic pressure wave from pressure waves measurements at peripheral locations such as the radial artery, brachial artery, carotid and/or femoral artery. See Chen, et al., Estimation of Central Aortic Pressure Waveform by Mathematical Transformation of Radial Tonometry Pressure. 95 Circulation 1827 (1997). The transfer function used for this estimate may be generalized, in the sense that the same generally applicable and sufficiently reliable transfer function is used to determine the aortic pressure wave for all patients. The transfer function can be different for known significantly different subpopulations, so that one transformation is applicable and sufficiently reliable for one group (men, for example) while a different transformation is applicable and sufficiently reliable for another group (women, for example. The transfer function can be individualized, such that, for each individual patient, a different transfer function is determined, and then used to estimate the aortic pressure wave from peripheral pressure waves. Use of non-invasive measurements to estimate aortic pressure wave allows for control of a chest compression device based on the pressure waveform in the field. (Waveforms obtained by invasive pressure sensors in the aorta might also be used in hospital, where it is more appropriate to install devices in the aorta of a patient).
Pulse wave velocity is used as a measure of arterial stiffness. It is defined as the velocity at which a pressure wave, travelling from the proximal aorta, travels to peripheral cites such as the superficially accessible portions of the carotid, brachial, radial or femoral arteries.
Pulse transit time is defined as the time it takes for a pulse waveform to travel from one location to another in the body. For example, the pulse transit time may be specified as the time it takes for a peak of the pulse pressure to travel from a proximal location to a more distal location in the arm, or from the carotid artery in the neck to the radial artery at the wrist. In some references, pulse transit time (PTT) is defined as the time it takes for the arterial pulse pressure wave, starting from the aortic valve, to reach a peripheral site. Pulse transit time is dependent on the resistance to flow presented by the peripheral blood vessels. High peripheral resistance is beneficial during CPR, because it limits blood flow to the peripheral blood vessels and thus forces any blood flow induced by compressions to the heart and brain.
Various values of these parameters have been associated with cardiovascular disease and risk of heart attack and stroke. They may be valuable in predicting the risk of future course of cardiovascular disease. These parameters have not been used as feedback for modification of resuscitation efforts for a patient in cardiac arrest. During sudden cardiac arrest and CPR chest compressions, some of the parameters become meaningless, while some parameters provide useful information pertaining to the course of CPR compressions and resuscitation. Some of the parameters, or related parameters, used for diagnosis can be used as feedback for control of CPR compression devices, while some related parameters defined below, which are meaningful solely in relation to CPR compressions, can be used as feedback for control of CPR compression devices.
The devices and methods described below provide for optimized treatment of patients in cardiac arrest. Using tonometric data obtained from the patient, various blood vessel parameters can be determined. Based on the value of the blood vessel parameters, resuscitation efforts can be varied to enhance blood flow induced by CPR compressions, and hence enhance the chances of reviving the patient. Aspects of resuscitation that may be varied in response to blood vessel parameters include various chest compression parameters which can be varied to optimize blood flow as indicated by blood vessel parameters and the administration of epinephrine, which may be administered or avoided depending on the determined values of blood vessel parameters.
The pulse pressure waveform is used to determine the health of the cardiovascular system of a patient.
The SPTI is an indicator of coronary perfusion and cerebral perfusion. Thus, the pulse pressure waveform may be analyzed to determine the health of a patient. Features of the pulse pressure waveform which are indicators of good blood flow and good vascular tone include:
The relationship of the CPR compression cycle and the resultant CPR-induced pulse waves and corresponding pulse pressure waveform is depicted in
The waveforms of
The waveforms of
The CPR compression device includes an input device 22, such as a touchscreen or keyboard or pushbuttons, and an output device such as a display screen (which may be integral with the touchscreen input device) and/or audio speakers, all interoperable with the control system to accept input from a user or provide output to a user. The input device is operable, by a user, to initiate operation of the device, and provide inputs to the control system.
The compression regimens are preferably predetermined in the sense that they are programmed by the manufacturer of the device at the time of manufacture, and can be selected by the control system in response to feedback, as described below, and are not subject to alteration by an operator while in use. However, if it is desirable to allow alteration of the compression regimen by CPR providers, at the point of use, the control system can be programmed to accept user input and alter the compression regimen according to operator input during or immediately before use.
In addition to the compression device, the system for implementing the methods described herein includes peripherally located non-invasive sensor 23 mounted on the patient's arm (on the medial side of the arm over the radial or brachial artery) and noninvasive sensor 24 on the patient's neck, mounted over the patient's common carotid artery. These and other peripherally located surface mounted tonometric sensors can be used to obtain peripheral tonometric information, such as CPR-induced pulse waves, from which the aortic pulse pressure waveform can be determined, and generate signals indicative of blood pressure or CPR-induced pulse waves of the cardiac arrest victim. These sensors may be any tonometric sensor, pulse velocity sensor, or pulse pressure sensor. The flexible pressure sensors described in Schwartz, et al., Flexible Polymer Transistors With High Pressure Sensitivity For Application In Electronic Skin And Health Monitoring. 4 Nature Communications 1859 (2013), for example, include two or more pressure sensing elements closely spaced (about 0.2 inches apart) on a flexible substrate 26. The sensors can measure pressures at intervals 100 milliseconds or less. With an array of these sensors 25, including a plurality of such sensors mounted in a flexible substrate 26, which in turn is mounted on the skin of the cardiac arrest victim (for example at the wrist, secured with a band or adhesive strip), a two-dimensional map of pressure over the area covered by the array of sensors can be obtained. This two-dimensional map can be analyzed by the control system to determine the pulse pressure wave passing through a peripheral artery over which the array is disposed, with certainty that the array will capture the pressure wave.
To use input from these sensors, the control system is programmed to accept the tonometric signals indicative of the blood pressure or CPR-induced pulse of the cardiac arrest victim generated by the tonometric sensors, and produce an aortic pulse pressure waveform based on the tonometric signals. The control system is further programmed to determine one or more characteristics of the pulse pressure waveform. These characteristics can include the area under a specified portion of the CPR-PPW (the CPR-SPTI, the CPR-DPTI, the total CPR-PTI) the pseudo-reflection inflection point, the peak pulse pressure, pulse transit time, etc. (Though impractical in the field, tonometric data can be obtain in hospital settings with tonometric sensors disposed within the aorta of the patient, and this data can be used as feed back for the CPR compression device.)
To determine the optimum compression regimen, which includes combinations and sub-combinations of compression parameters such as compression depth, compression rate, compression rise time, compression hold time, and release velocity, the compression device may initially, and occasionally during the course of CPR compressions, test various compression regimens, determine the resultant pulse pressure waveform characteristics from each distinct compression regimen, and compare the characteristics and thereafter perform compressions according to the regimen that provides the most favorable pulse pressure waveform characteristics. The control system is thus programmed to determine the effectiveness of chest compression by operating the compression device at a first regimen, a second regimen, a third regimen, and so on, (each distinct regimen will include a variation of one or more of the compression parameters), thus testing a cardiac victim upon initiation of CPR compressions with several compression regimens accomplished in several sets of test compressions, and experimentally and preferably non-invasively determining the compression waveform that provides the best aortic pulse pressure waveform. The aortic pulse pressure waveform is preferably estimated using a peripheral pressure waveform as an input to a generalized transfer function (though it can be measured invasively), and the control system is programmed to accept peripheral waveform signals, apply the transfer function to those signals, and derive estimated aortic pulse pressure waveforms. From the estimated aortic pulse pressure waveform, the control system determines a parameter or characteristic of the pulse pressure waveform, which can be one of the several characteristics. The input peripheral pulse pressure wave form is produced by the action of the chest compression device. The system performs a series of test compressions with different compression parameters (including one or more parameters such as compression depth, compression rate, compression rise time, compression hold time, release velocity, etc., alone or in various permutations) to determine which of several chest compression regimens provides the best aortic pulse pressure waveform (on the basis of parameters such as peak pressure, a pressure time integral such as DPTI, SPTI, TTPI, detection of a the pseudo-reflection inflection point or notch or a combination of these). For example, the control system is programmed to perform initial test compression sets of 5 to 10 compressions, according to several varied compression regimens (the number is of test sets is not critical, and be enlarged or limited as clinical experience dictates), as follows:
After collecting various CPR pulse pressure waveforms, the control system determines, based on predetermined criteria, which pulse pressure waveform represents the optimum blood flow criteria which may be the largest CPR-SPTI (which is associated with the compression period), or CPR-DPTI (which is associated with the release period), or CPR-TPTI (which is associated with the entire compression cycle), or the largest or earliest pseudo-reflective notch, or the highest peak pressure. We currently prefer the CPR-SPTI as the parameter most likely to associated with effective CPR-compression-induced blood flow. When the pressure time integrals are used, the largest value is considered to indicate the best blood flow. For the detection of the pseudo-reflective notch, the earliest appearance of the notch is indicative of the optimum blood flow. After making this determination of the optimum pulse pressure waveform, the control system, according to its programming, operates the chest compression device to provide therapeutic chest compressions according to the compression regimen that corresponds to the optimum pulse pressure waveform. Sets of therapeutic compression can include uninterrupted, continuous compressions at a resuscitative rate for several minutes, or extended periods of typical compression sets of 30 compressions, interrupted for rescue breathing, repeated until the patient is revived, or CPR is suspended for defibrillation or follow-on care, or the CPR efforts are abandoned when the patient is no longer subject to resuscitation. (Note that the test compression sets described above may all be effective as therapeutic chest compressions, so that test compressions and test compression sets may be viewed as a subset of the therapeutic compressions.)
From time to time, over the course of CPR resuscitation effort including many chest compressions applied in sets of 15 compressions or applied continuously for several minutes, the system operates to alter the chest compression regimen, running through the several regimens, to again test the patient to update the determination of the optimum chest compression regimen, and thereafter continues compressions using the regimen that provides the optimum blood flow as indicated by the chosen parameter. This is beneficial because the tone (the compliance and elastance) of the patient's vasculature, especially the aorta, tends to degrade over the course of CPR compressions, so that the optimum compression regimen may change over an extended course of CPR compressions.
Summarizing the method described above, the method entails providing CPR compressions on a cardiac arrest victim, obtaining compression induced pulse pressure waveforms caused by the chest compressions, and adjusting a parameter of the chest compressions based on a characteristic of the pulse pressure waveforms. The method can be performed according to the following steps:
In this method, the characteristic may be any one of the characteristics mentioned above (including CPR-SPTI, CPR-DPTI, CPR-TPTI, or the largest or earliest pseudo-reflective notch, or the highest peak pressure.) The preferred characteristic may be varied as clinical experience dictates, and additional characteristics may be identified which also prove useful in the method.
For a long course of CPR chest compressions, the method may also include periodically repeating the step of determining a characteristic of compression induced pulse pressure waveforms for different pair of subsets of compressions performed under differing compression regimens, comparing the characteristics of each new subset of compressions, and determining which of the differing compression regimens is likely to provide the better CPR-induced blood flow, and then continuing to perform chest compressions according to the chest compression regimen determined to be likely to provide better CPR-induced blood flow. The different pair of subsets can include compressions performed according to the originally determined optimum regimen, and a regimen expected to be most appropriate to a patient exhibiting degraded compliance, or the regimens may both be different from the regimen in effect at the time the new comparison is made.
Vascular tone may degrade during the course of CPR. Vascular tone is indicated by arterial compliance/elastance, which can be measured and/or estimated with pulse transit time. Epinephrine is administered under the theory that it restores elasticity beneficial to reduce vascular stiffness and improve vascular elastance, and increase diastolic pressure, which is beneficial to CPR blood flow. On the other hand, epinephrine tends to lower blood oxygen levels. Thrush, et al., Is Epinephrine Contraindicated During Cardiopulmonary Resuscitation?, 96 Circulation 2709 (1997), It would therefore be helpful to avoid administration of epinephrine unless it is helpful in improving vascular tone.
Arterial stiffness (compliance/elastance) can be determined during the course of CPR compressions by measuring the CPR pulse wave velocity or pulse transit time. In healthy patients, aortic pulse wave velocity ranges from 5 meters per second to 15 meters per second. During CPR, the CPR pulse wave velocity is initially expected to be less, but the absolute or instantaneous value of the pulse wave velocity is not necessarily informative, although extreme stiffness may indicate a need for epinephrine without further information. Changes in the pulse wave velocity over the course of CPR compressions, and/or in response to administration of epinephrine, however, may be informative regarding the need for epinephrine, the effect of administration, or the need to discontinue or continue administration of epinephrine.
Over the course of CPR, the arterial stiffness is likely to increase. This degrades the Windkessel effect of the arteries, and thus degrades the effectiveness of CPR. Continuous or occasional determination of arterial compliance/elastance/pulse wave velocity during the course of CPR compressions can be used to determine the need for epinephrine. Based on changes, or lack of change, in arterial compliance/elastance/pulse wave velocity subsequent to administration of epinephrine during the course of CPR compression, the beneficial effect of epinephrine, or lack of effect of epinephrine on vascular tone can be assessed, and further decisions to administer epinephrine can be made based on this information. Alternately, based on the change of arterial compliance/elastance/pulse wave velocity over the course of CPR compressions, epinephrine may be avoided initially, and administered when arterial stiffness degrades by a predetermined level relative to the initially determined level, such as 20% of the level determined at the start of a resuscitation effort, during a compression set accomplished early in a resuscitation effort.
Alternatively, based on absolute values of arterial compliance/elastance/pulse wave velocity, epinephrine may be avoided for patients with an arterial stiffness estimated at typical values for healthy patients. Using pulse wave velocity as a measurement of, or a proxy for, arterial stiffness, typical values pulse wave velocity varies by age as follows:
(These numbers are drawn from Determinants Of Pulse Wave Velocity In Healthy People And In The Presence Of Cardiovascular Risk Factors: ‘Establishing Normal And Reference Values’. European 31 Heart Journal 2338 (2010), and refer to pulse wave velocity determined from two characteristics points on carotid and femoral waveforms. These values will likely vary when assessed at different peripheral sites, and also with the algorithm used to determine pulse wave velocity from the waveforms.) For patients displaying compliance/elastance/pulse wave velocity typical of patients their age, or within about 30% of these normative values, the control system can be programmed to advise a CPR provider to avoid administration of epinephrine (to support this function, the control system must be programmed to accept user input or other input providing the age of the patient, or an estimate of the age of the patient).
Epinephrine may be administered immediately for patients with an arterial stiffness estimated at 4.0 meters per second or less (using pulse wave velocity as a measurement of, or a proxy for, arterial stiffness). Under a similar regimen, Epinephrine may be administered immediately for patients with an arterial stiffness estimated at some significant deviation from the mean or median pulse wave velocity for their age group (for example, a PWV falling below 70%, or some other predetermined percentage, of the mean or median for their age group) or some significant deviation from a mean or median for all patients or a portion of the expected patient population (for example, the mean for the 50-59 year old population of 8.3 can be taken as a value for which epinephrine is not indicated, and values falling significantly below this level can be taken as a value for which epinephrine is indicated.
The numbers expressed in the previous paragraphs regarding arterial stiffness/compliance/pulse wave velocity may be adjusted as clinical experience dictates.
In the first method, the control system operates to accept input from the chest compression device indicating the state of the compression waveform (for example, identifying the time of the start of a compression, which is analogous to the foot of the aortic pulse pressure waveform) and accept input from surface mounted peripheral tonometric sensors (for example, located at the carotid, brachial, radial, or femoral arteries) to detect the arrival of a pulse pressure waveform at one or more of these peripheral locations, and from this information determine a measure of arterial stiffness. The control system is also programmed to accept user input, from an associated user input device, which indicates that epinephrine has been administered. The control system continues assessing arterial stiffness, and provides output indicating that arterial stiffness has been improved, or unaffected, subsequent to the administration of epinephrine.
These decisions regarding arterial stiffness may be made on the basis of CPR pulse wave velocity, which is used as a proxy for arterial stiffness. Pulse wave velocity is typically measured from the beginning of a heartbeat, as indicated by an ECG waveform, but for a patient in cardiac arrest the ECG is unrelated to the CPR compressions which initiate the CPR-induced pulse and pulse wave, so for the purpose of determining pulse wave velocity during CPR (a CPR Pulse wave velocity), we use the start of the compression stroke of the compression device as the starting point for measuring pulse wave velocity. Thus, the control system is programmed to accept input from the CPR compression device indicating the start of a compression, and tonometric signals from a peripherally mounted tonometric sensor to determine the arrival of a CPR-induced pulse at a peripheral location (the carotid or femoral artery), to determine the CPR pulse wave velocity.
To effectuate this method, the control system of the chest compression device and/or defibrillator and/or free standing control system can be programmed to accept inputs regarding the timing of chest compressions, the pulse waveforms measured at peripheral cites, and determine parameters such as pulse wave velocity, arterial stiffness and/or augmentation index (alone or in combination), and compare these values (1) against values previously obtained in earlier compression and thereby determine that epinephrine is or is not indicated, and provide prompts to a CPR provider to avoid epinephrine or administer epinephrine based on that determination or (2) against predetermined values chosen on the basis that they indicate that epinephrine may or may not be beneficial to improve the effectiveness of CPR chest compressions, and thereby determine that epinephrine is or is not indicated, and provide prompts to a CPR provider to avoid epinephrine or administer epinephrine based on that determination.
While the preferred embodiments of the devices and methods have been described in reference to the environment in which they were developed, they are merely illustrative of the principles of the inventions. The elements of the various embodiments may be incorporated into each of the other species to obtain the benefits of those elements in combination with such other species, and the various beneficial features may be employed in embodiments alone or in combination with each other. Other embodiments and configurations may be devised without departing from the spirit of the inventions and the scope of the appended claims.
This application is a continuation under 35 U.S.C. § 120 of U.S. patent application Ser. No. 14/659,612, filed Mar. 16, 2015 which claims benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application Ser. No. 61/955,109 filed Mar. 18, 2014. All subject matter set forth in each of the above referenced applications is hereby incorporated by reference in its entirety into the present application as if fully set forth herein.
Number | Name | Date | Kind |
---|---|---|---|
3651801 | Kullok | Mar 1972 | A |
4059099 | Davis | Nov 1977 | A |
4088138 | Diack et al. | May 1978 | A |
RE30372 | Mirowski et al. | Aug 1980 | E |
4296755 | Judell | Oct 1981 | A |
4355634 | Kanter | Oct 1982 | A |
4588383 | Parker et al. | May 1986 | A |
4610254 | Morgan et al. | Sep 1986 | A |
4619265 | Morgan et al. | Oct 1986 | A |
4680708 | Ambos et al. | Jul 1987 | A |
4863385 | Pierce | Sep 1989 | A |
4928674 | Halperin et al. | May 1990 | A |
5077667 | Brown et al. | Dec 1991 | A |
5092341 | Kelen | Mar 1992 | A |
5109862 | Kelen et al. | May 1992 | A |
5247945 | Heinze et al. | Sep 1993 | A |
5285792 | Sjoquist et al. | Feb 1994 | A |
5289823 | Eckerle | Mar 1994 | A |
RE34800 | Hutchins | Nov 1994 | E |
5391187 | Freeman | Feb 1995 | A |
5466244 | Morgan | Nov 1995 | A |
5474574 | Payne et al. | Dec 1995 | A |
5496257 | Kelly | Mar 1996 | A |
5511553 | Segalowitz | Apr 1996 | A |
5562710 | Olsen et al. | Oct 1996 | A |
5589639 | D Antonio et al. | Dec 1996 | A |
5591213 | Morgan | Jan 1997 | A |
5611815 | Cole et al. | Mar 1997 | A |
5617853 | Morgan | Apr 1997 | A |
5619265 | Suzuki et al. | Apr 1997 | A |
5645571 | Olson et al. | Jul 1997 | A |
5662690 | Cole et al. | Sep 1997 | A |
5683424 | Brown et al. | Nov 1997 | A |
5700281 | Brewer et al. | Dec 1997 | A |
5735879 | Gliner et al. | Apr 1998 | A |
5755671 | Albrecht et al. | May 1998 | A |
5957856 | Weil et al. | Sep 1999 | A |
6010457 | O≢Rourke et al. | Jan 2000 | A |
6125299 | Groenke et al. | Sep 2000 | A |
6171257 | Weil et al. | Jan 2001 | B1 |
6174295 | Cantrell et al. | Jan 2001 | B1 |
6178357 | Gliner et al. | Jan 2001 | B1 |
6201992 | Freeman | Mar 2001 | B1 |
6224562 | Lurie et al. | May 2001 | B1 |
6246907 | Lin et al. | Jun 2001 | B1 |
6263238 | Brewer et al. | Jul 2001 | B1 |
6308094 | Shusterman et al. | Oct 2001 | B1 |
6331162 | Mitchell | Dec 2001 | B1 |
6351671 | Myklebust et al. | Feb 2002 | B1 |
6390996 | Halperin et al. | May 2002 | B1 |
6393316 | Gillberg et al. | May 2002 | B1 |
6418342 | Owen et al. | Jul 2002 | B1 |
6427685 | Ray, II | Aug 2002 | B1 |
6438419 | Callaway et al. | Aug 2002 | B1 |
6496731 | Lovett | Dec 2002 | B1 |
6558335 | Thede | May 2003 | B1 |
6589267 | Hui | Jul 2003 | B1 |
6597943 | Taha et al. | Jul 2003 | B2 |
6658290 | Lin et al. | Dec 2003 | B1 |
6662032 | Gavish et al. | Dec 2003 | B1 |
6671545 | Fincke | Dec 2003 | B2 |
6687540 | Marcovecchio | Feb 2004 | B2 |
6740045 | Amano | May 2004 | B2 |
6805672 | Martin et al. | Oct 2004 | B2 |
6827695 | Palazzolo et al. | Dec 2004 | B2 |
6865413 | Halperin et al. | Mar 2005 | B2 |
6872080 | Pastrick et al. | Mar 2005 | B2 |
6961612 | Elghazzawi et al. | Nov 2005 | B2 |
7056295 | Halperin | Jun 2006 | B2 |
7074199 | Halperin et al. | Jul 2006 | B2 |
7108665 | Halperin et al. | Sep 2006 | B2 |
7190999 | Geheb et al. | Mar 2007 | B2 |
7220235 | Geheb et al. | May 2007 | B2 |
7311680 | Lenhart et al. | Dec 2007 | B2 |
7410470 | Escudero et al. | Aug 2008 | B2 |
7570993 | Weil et al. | Aug 2009 | B2 |
7650181 | Freeman et al. | Jan 2010 | B2 |
7946994 | Finburgh et al. | May 2011 | B2 |
7993290 | Lund et al. | Aug 2011 | B2 |
8034006 | Celik-Butler et al. | Oct 2011 | B2 |
8333720 | Nysaether | Dec 2012 | B2 |
8394040 | Strand et al. | Mar 2013 | B2 |
8408207 | Steen et al. | Apr 2013 | B2 |
8511308 | Hecox et al. | Aug 2013 | B2 |
8532765 | Ochs et al. | Sep 2013 | B2 |
8560245 | Li et al. | Oct 2013 | B2 |
8690804 | Nilsson et al. | Apr 2014 | B2 |
8712493 | Ukawa | Apr 2014 | B2 |
8731658 | Hampton et al. | May 2014 | B2 |
8738129 | Packer et al. | May 2014 | B2 |
8744542 | Ukawa | Jun 2014 | B2 |
8876742 | Centen | Nov 2014 | B2 |
8903498 | Sullivan et al. | Dec 2014 | B2 |
9198826 | Banville et al. | Dec 2015 | B2 |
9248306 | Joo et al. | Feb 2016 | B2 |
9259543 | Paradis et al. | Feb 2016 | B2 |
9357934 | Watson et al. | Jun 2016 | B2 |
9486390 | Centen et al. | Nov 2016 | B2 |
9861311 | Freeman et al. | Jan 2018 | B2 |
10143619 | Chapman et al. | Dec 2018 | B2 |
20020047140 | Moller et al. | Apr 2002 | A1 |
20020165585 | Dupelle et al. | Nov 2002 | A1 |
20030163051 | Eckerle et al. | Aug 2003 | A1 |
20050137929 | Frazier et al. | Jun 2005 | A1 |
20100022886 | Ayati et al. | Jan 2010 | A1 |
20110184759 | Selker et al. | Jul 2011 | A1 |
20110301513 | Freeman | Dec 2011 | A1 |
20120041313 | Tanaka et al. | Feb 2012 | A1 |
20120191476 | Reid et al. | Jul 2012 | A1 |
20120220887 | Fossan | Aug 2012 | A1 |
20140135634 | Pranevicius et al. | May 2014 | A1 |
20140277228 | Quan et al. | Sep 2014 | A1 |
20150018823 | Centen | Jan 2015 | A1 |
20150164417 | Tupin, Jr. | Jun 2015 | A1 |
20150283027 | Lampe et al. | Oct 2015 | A1 |
20160317385 | Salcido et al. | Nov 2016 | A1 |
Entry |
---|
US 6,303,107 B1, 10/2001, Myklebust et al. (withdrawn) |
Chen, et al., Estimation of Central Aortic Pressure Waveform by Mathematical Transformation of Radial Tonometry Pressure, 95 Circulation 1827 (1997). |
Schwartz, et al., Flexible Polymer Transistors with High Pressure Sensitivity for Application in Electron Skin and Health Monitoring, 4 Nature Communications 1859 (2013). |
Thrush, et al., Is Epinephrine Contraindicated During Cardiopulmonary Resuscitation?, 96 Circulation 2709 (1997). |
Determinants of Pulse Wave Velocity in Healthy People and in the Presence of Cardiovascular Risk Factors: Establishing Normal and Reference Values, European 31 Heart Journal 2338 (2010). |
Number | Date | Country | |
---|---|---|---|
20200222277 A1 | Jul 2020 | US |
Number | Date | Country | |
---|---|---|---|
61955109 | Mar 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14659612 | Mar 2015 | US |
Child | 16741925 | US |